the interpretation of spectra (the accuracy of MS/MS sequencing algorithms remains low with only ~30% of spectra correctly reconstructed [7] [8] [9] ). Bridging this MS/MS sequencing gap not only significantly reduces the total sequencing time but also considerably reduces the sequencing costs and required expertise (no need for additional Edman+cDNA sequencing instrumentation).
We have recently introduced shotgun protein sequencing (SPS) based upon MS/MS spectra from overlapping peptides 10, 11 . Although we demonstrated the feasibility of assembling MS/MS spectra from snake venoms into long protein contigs, assembling spectra into intact proteins requires additional experimental and computational challenges to be addressed 10 . Key experimental challenges include optimizing protease cocktails for generating rich peptide ladders and adopting the new generation of highly accurate mass spectrometers for SPS. The key computational challenge is not unlike "comparative fragment assembly" in classic DNA sequencing when a known genome (e.g., human) is used as a template for assembling another genome (e.g., macaque) 12 .
On this basis, we developed CSPS for assembling spectra into unknown proteins using known proteins as templates (http:// proteomics.bioprojects.org/Software.html). Using CSPS, we are able to sequence de novo unknown mAbs in <36 h. We further demonstrate that CSPS identifies unexpected modifications that would frequently go unrecognized by either Edman sequencing or MS/MS database searching.
We obtained two mAbs that had been raised against the B-and T-cell lymphocyte attenuator molecule (BTLA): a firstgeneration antibody (aBTLA) and a mutated version of the original species (mt-aBTLA). Antibodies were raised in mice against human BTLA and were selected for their ability to attenuate T-cell responses in vitro to protect against graft-versus-host disease. The antibodies were separately digested with Lys-C, Glu-C, Asp-N, chymotrypsin, pepsin and trypsin, and the resulting peptide mixtures were analyzed with linear ion trap Fourier transform ion cyclotron mass spectrometry (LTQ-FTMS) and linear ion trap orbital trapping mass analyzer (LTQOrbitrap) instruments (Supplementary Data online).
De novo MS/MS sequencing is complicated by incomplete peptide fragmentation and unexplained peaks. SPS addresses this difficulty with a three-stage alignment→assembly→consensus approach 10 plant and yeast to mammals [3] [4] [5] . A screen could be developed to examine variants of existing, well-characterized, compounds for leads, and a selection could be used for testing for either natural or designed novel compounds. StopGo requires a particular sequence as part of the nascent peptide within the ribosome and tRNA Pro in the ribosomal A-site. Because several antibiotics are known to target/bind within the peptide exit tunnel of the ribosome, the possibility of identifying a compound that uniquely targets the vital StopGo action merits consideration (the human pathogens, Vilyuisk, Saffold and possibly some Parecho-type viruses, also use StopGo).
Two aspects make this strategy attractive. First, the short nascent peptide sequence specifying StopGo functions in heterologous polyprotein contexts: the sequence can be flanked not by FMDV sequences, but by reporter proteins or selectable markers. No infectious agent is required to study StopGo. And second, StopGo has been demonstrated in diverse cell types ranging from insect,
Automated de novo protein sequencing of monoclonal antibodies To the Editor:
De novo protein sequencing of monoclonal antibodies (mAbs) is required when cDNA or the original cell line is not available, or when characterization of post-translational modifications is needed to verify antibody integrity and effectiveness. Here, we demonstrate that comparative shotgun protein sequencing (CSPS) based on tandem mass spectrometry can reduce the time required to sequence a mAb to 36 h, a dramatic reduction as compared to the classic Edman degradation. We therefore argue that CSPS has the potential to be a disruptive technology for all protein sequencing applications.
Antibodies have been exploited as indispensable reagents for biomedical research and as diagnostic and therapeutic agents 1, 2 . The specificity and effector functions of antibodies are highly dependent on the amino acid sequence and the presence (or absence) of specific modifications 3 . Although DNA sequencing is routinely used in the initial characterization of mAbs, subsequent mutations and modifications are typically recognized by analysis at the protein level. Pre-clinical antibodies may be derived from immunized hosts, commercial sources, gifts from collaborators or from hybridomas that no longer secrete antibody and for which the cDNA is not available. It is therefore critical to sequence the antibodies to monitor the integrity of the molecule, to troubleshoot performance in pre-clinical assays, to regenerate cDNA by reverse engineering, and to perform quality control 4 . In addition, protein-level rearrangements (e.g., observed on IG4 antibodies) can be revealed only by protein level analysis.
Sequencing of (unknown) proteins (and antibodies in particular) remains a challenge. Because antibodies are not directly inscribed in the genome and are constantly created anew, tandem mass spectrometry (MS/MS) database search approaches are not applicable, making Edman degradation the only viable option 5 . This is a lowthroughput and time-consuming approach since it is characterized by short peptide reads (limited to about 30 amino acids (aa)) and requires proteolytic digestion, peptide fractionation and peptide-bypeptide sequencing. Mass spectrometry can rapidly generate data that can be used either for cDNA primer design (followed by ≈2 weeks of additional experiments) or combined with Edman degradation to expedite sequencing 6 . Although this hybrid MS/MS+Edman approach has been applied to de novo sequencing of antibodies 4 , the Achilles' heel of MS/MS sequencing has been and Supplementary Data). Comparison of the CSPS contigs with the Edman degradation data revealed that the three sequence gaps not covered by CSPS contigs had no coverage by MS/MS spectra. Thus, these gaps were caused by particularities of the sequence that hinder MS/MS analysis rather than by shortcomings of CSPS algorithm. For example, the [(N)STFRSV(S)] gap contains the NXT motif indicative of glycosylation. Indeed, Asn297 is typically glycosylated and this impedes the identification of these fragments. In addition to this area the first three N-terminal amino acids are missing since the N-terminal peptides were either too short (<6 aa) or too long (>18 aa) for MS/MS identifications. CSPS results on mt-aBTLA were similar with 97% sequence coverage for three contigs of lengths 292, 40 and 97. In addition, this sequence clearly illustrates the ability of CSPS to predict multiple mutations and modifications-25 out of 28 (89%) mass offsets from the closest homologous protein correctly matched the target sequence (see Supplementary Data).
It turned out that the sequence gaps were identical to the corresponding regions in the homologous proteins. When combined with the resulting match to the mass of the intact protein, these identical homologies could be used to connect the long contigs into a contiguous sequence (this step should be taken with caution because multiple spectrum of the protein. The resulting 'long' theoretical spectra of the selected proteins are further assembled with real spectra/ contigs using the shotgun protein sequencing tool 11 . The theoretical protein spectra serve as the 'glue' connecting SPS contigs that map to at least one common mass on the same theoretical spectrum (ClustalW alignments are used to map multiple homologous proteins to the same reference protein; see Supplementary Data for details). Sets of contigs matched to the same protein but without common masses on the protein spectrum are still ordered but not glued into the same CSPS contig. After application of SPS, a consensus sequence is again derived using only the mass differences determined from the overlapped spectra (that is, homology glues contigs but does not directly influence the resulting protein sequence).
The CSPS assembly of aBTLA heavy chain contigs is illustrated in Figure 2 . To validate our approach, all resulting CSPS contigs were compared with the aBTLA sequence obtained by manual Edman degradation sequencing (and MS/MS database search in the constant regions).
SPS resulted in 63 contigs covering 95% of the aBTLA heavy chain (not counting contigs from proteases and contaminants); grouped by CSPS into three long contiguous regions (CSPS contigs) of lengths 288, 40 and 92 aa using two homologous proteins (see Fig. 2 similar to DNA fragment assembly (Fig. 1) . The alignment stage identifies 'spectral alignments' from overlapping peptides 11 , the assembly stage combines the spectral alignments into 'spectral contigs' and the consensus stage determines the sequences of spectral contigs resulting in 'protein contigs' . Unlike DNA assembly that aligns (unambiguous) DNA reads, SPS aligns uninterpreted spectra of modified and unmodified peptides alike, each of which could be interpreted in thousands of different ways (possible de novo peptide reconstructions).
CSPS complements SPS through the use of homologous sequences from known proteins (e.g., known antibodies) as templates to assemble unknown proteins. CSPS first constructs a set of homologous proteins by matching the SPS contigs against the protein database (all National Center for Biotechnology Information (NCBI)-nr rat/ mouse sequences were used here; ftp.ncbi. nlm.nih.gov:/refseq) and further scores each protein by the overall alignment score of all contigs matched to this protein (see Supplementary Data for algorithmic details). All proteins with scores above the threshold are selected and the theoretical spectra of these proteins are constructed. For our purposes, the theoretical spectrum of a protein is the set of all possible b-ions representing an 'idealized' top-down a b
24 Assembled spectra 11 Assembled spectra Figure 1 Protein contigs resulting from shotgun protein sequencing of aBTLA tandem mass spectra. (a) Protein contig resulting from 24 spectra from the aBTLA heavy chain. each spectrum is shown superimposed with a sequence of arrows indicating its sequence of recovered masses; modified variants of the consensus sequence are indicated by red arrows (six different modifications on seven spectra). In many cases, the red arrows show a series of amino acids rather than a single amino acid (the exact positions can be inferred later, for example, using Unimod database). (b) Protein contig illustrating the variety of discovered modifications on or next to cys-146 (aBTLA heavy chain); modified residues are indicated with red labels next to the corresponding edge: c+57 (the expected mass, spectra 1,7, not highlighted), c+71 (acrylamide adduct, spectra 2,3,8,11), c-34 (dehydroalanine (DHA), spectra 4,5), DHA+16 (oxidation, spectrum 6), M+16 (oxidation, spectra 1,3), either c+209 or DHA+243 (spectrum 9), either c+223 or DHA+257 (spectrum 10).
c o r r e s P o n D e n c e sequence coverage versus ≈10% for Edman sequencing), greatly speeds up the analytical protocol and allows one to automatically discover post-translational modifications. Thus, CSPS opens a possibility to correlate unexpected modifications with changes in antibody efficiency while simultaneously tracking mutations. Also, CSPS is already faster than the cDNA sequencing route commonly used in many laboratories 15 .
Although we demonstrated that CSPS can automatically sequence antibodies, further efforts are needed to improve its efficiency, reliability and robustness. An important direction is to assign reliability scores to amino acids, further optimize the protease cocktails and incorporate complementary MS/MS fragmentation such as electron transfer dissociation.
